For the roughly 1.3 billion adults worldwide living with hypertension, staying on a prescribed medication long enough for it to work is often the silent failure point of treatment. Understanding which drug classes and combinations actually drive patients to quit — rather than simply which ones lower numbers on a cuff — could reshape how clinicians sequence therapy from the very first prescription.
This large-scale network meta-analysis pooled data from short-term randomized clinical trials to simultaneously compare adverse event profiles and treatment discontinuation rates across major antihypertensive drug classes and their combinations. Rather than simple head-to-head comparisons, the network design allowed indirect comparisons across regimens that were never directly tested against each other in a single trial. The analysis examined how specific drug classes — including ACE inhibitors, angiotensin receptor blockers (ARBs), calcium channel blockers, diuretics, and beta-blockers — perform individually and in combination with respect to side-effect burden and the clinically critical outcome of patient dropout.
What makes this analysis particularly valuable is its focus on tolerability rather than efficacy alone. Most hypertension guidelines are built around blood pressure reduction targets, but real-world adherence is notoriously poor — estimated at below 50% within one year of initiation. If certain combinations produce meaningfully lower discontinuation rates without sacrificing antihypertensive effect, that tradeoff has direct implications for long-term cardiovascular risk reduction. ARBs have historically shown better tolerability than ACE inhibitors, largely by avoiding ACE inhibitor–associated cough, and calcium channel blockers carry their own discontinuation-driving side effects such as peripheral edema. Whether combination regimens compound or partially offset these tolerability liabilities is the central clinical question here. This study is notable in scope but remains bounded by the short-term duration of included trials; long-term tolerability patterns, patient comorbidities, and socioeconomic adherence barriers are not captured. Clinicians should treat these findings as directional rather than definitive for individual patient decisions.